Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma

Expert Opinion on Drug Metabolism & Toxicology
Claudia Maria Hattinger, Massimo Serra


Drug-metabolizing enzymes (DMEs) biotransform several toxins and xenobiotics in both tumor and normal cells, resulting in either their detoxification or their activation. Since DMEs also metabolize several chemotherapeutic drugs, they can significantly influence tumor response to chemotherapy and susceptibility of normal tissues to collateral toxicity of anticancer treatments. This review discusses the pharmacogenetics of DMEs involved in the metabolism of drugs which constitute the backbone of osteosarcoma (OS) chemotherapy, highlighting what is presently known for this tumor and their possible impact on the modulation of future treatment approaches. Achieving further insight into pharmacogenetic markers and biological determinants related to treatment response in OS may ultimately lead to individualized treatment regimens, based on a combination of genotype and tumor characteristics of each patient.


Jan 1, 1987·Archives of Toxicology·K W BockB S Bock-Henning
Jun 1, 1995·The Annals of Pharmacotherapy·R L Slaughter, D J Edwards
May 13, 1994·Journal of Medicinal Chemistry·M H LyttleL M Kauvar
Apr 29, 1998·JAMA : the Journal of the American Medical Association·J LazarouP N Corey
Jun 23, 1999·Proceedings of the National Academy of Sciences of the United States of America·P J JakobssonB Samuelsson
Aug 4, 1999·Trends in Pharmacological Sciences·M Ingelman-SundbergR A McLellan
Jan 7, 2000·American Journal of Epidemiology·S C CottonN Brockton
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·P J JakobssonB Persson
Dec 5, 2002·Pharmacogenetics·Federico InnocentiAnna Di Rienzo
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano FerrariGaetano Bacci
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hassan R DhainiLaurence H Baker
Dec 5, 2003·Journal of the American Chemical Society·Diana S HamiltonDonald J Creighton
Feb 20, 2004·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Phillip BarnetteCharles Keller
Nov 30, 2004·Cancer Investigation·William A Denny
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Michael, M M Doherty
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Beate Kempf-BielackKurt Winkler
Mar 5, 2005·Anti-cancer Drugs·Gabi U DachsGillian M Tozer
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·John D HayesIan R Jowsey
Sep 7, 2005·Pharmacogenomics·Paola Biason, Giuseppe Toffoli
Oct 4, 2005·The Lancet Oncology·Charity D ScriptureWilliam D Figg
Nov 19, 2005·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Partha Roy, David J Waxman
Mar 22, 2006·Oncogene·C Rodriguez-Antona, M Ingelman-Sundberg
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ji-Youn HanJin Soo Lee
Jul 25, 2006·Cancer Treatment Reviews·Alessandra LonghiGaetano Bacci
Feb 1, 2007·Blood·Shinji KishiMary V Relling
Jun 2, 2007·The Lancet Oncology·Jay S WunderBenjamin A Alman
Aug 8, 2007·Current Opinion in Pharmacology·Hui-Wen Lo, Francis Ali-Osman
Oct 16, 2007·Journal of Biochemical and Molecular Toxicology·F Peter Guengerich
Dec 7, 2007·Chemical Research in Toxicology·F Peter Guengerich
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ann M MoyerRichard M Weinshilboum
Aug 15, 2008·Cancer Research·Michela PaselloMassimo Serra
Sep 11, 2008·Reviews on Recent Clinical Trials·Akio Sakamoto, Yukihide Iwamoto
Jun 23, 2009·Anti-cancer Agents in Medicinal Chemistry·Paolo RuzzaLuigi Quintieri
Aug 20, 2009·Mini Reviews in Medicinal Chemistry·L GattiP Perego

❮ Previous
Next ❯


Jun 1, 2016·The Pharmacogenomics Journal·M Serra, C M Hattinger
Jun 30, 2016·Drug Discovery Today·Hanneke I VosDunja Maroeska W M Te Loo
Oct 21, 2016·Rheumatology and Therapy·Ryan A DurfeeHue H Luu
Dec 7, 2017·International Journal of Cancer. Journal International Du Cancer·Roelof KosterLisa Mirabello
Mar 2, 2019·Expert Opinion on Drug Metabolism & Toxicology·Claudia Maria HattingerMassimo Serra
Apr 17, 2020·Journal of Adolescent and Young Adult Oncology·Alini Trujillo-PaolilloSílvia R C Toledo
Apr 17, 2020·Cells·Katia ScotlandiMassimo Serra
Apr 14, 2017·Oncotarget·Alini Trujillo-PaolilloSilvia Regina Caminada de Toledo
Mar 25, 2017·Nature Reviews. Endocrinology·D Matthew GianferanteSharon A Savage
Oct 17, 2018·Expert Review of Molecular Diagnostics·Claudia Maria HattingerMassimo Serra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Related Papers

Expert Opinion on Drug Metabolism & Toxicology
Mona Arab-AlameddineChantal Csajka
Expert Opinion on Drug Metabolism & Toxicology
Helena JoyceAnnemarie Larkin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M Michael, M M Doherty
Clinica Chimica Acta; International Journal of Clinical Chemistry
Werner Steimer, Julia M Potter
© 2021 Meta ULC. All rights reserved